- Home
- USEA vs IMRN Comparison
USEA vs IMRN Comparison
Compare USEA & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USEA
- IMRN
- Stock Information
- Founded
- USEA 2004
- IMRN 1994
- Country
- USEA Greece
- IMRN Australia
- Employees
- USEA N/A
- IMRN N/A
- Industry
- USEA Marine Transportation
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- USEA Consumer Discretionary
- IMRN Health Care
- Exchange
- USEA Nasdaq
- IMRN Nasdaq
- Market Cap
- USEA 17.2M
- IMRN 15.0M
- IPO Year
- USEA N/A
- IMRN N/A
- Fundamental
- Price
- USEA $1.84
- IMRN $2.11
- Analyst Decision
- USEA Strong Buy
- IMRN Strong Buy
- Analyst Count
- USEA 1
- IMRN 1
- Target Price
- USEA $6.00
- IMRN $5.00
- AVG Volume (30 Days)
- USEA 74.9K
- IMRN 6.2K
- Earning Date
- USEA 02-18-2025
- IMRN 12-31-2024
- Dividend Yield
- USEA 16.30%
- IMRN N/A
- EPS Growth
- USEA N/A
- IMRN N/A
- EPS
- USEA N/A
- IMRN N/A
- Revenue
- USEA $46,160,000.00
- IMRN $3,271,194.00
- Revenue This Year
- USEA $27.55
- IMRN N/A
- Revenue Next Year
- USEA $5.76
- IMRN N/A
- P/E Ratio
- USEA N/A
- IMRN N/A
- Revenue Growth
- USEA 11.18
- IMRN 171.67
- 52 Week Low
- USEA $1.72
- IMRN $1.59
- 52 Week High
- USEA $3.00
- IMRN $5.96
- Technical
- Relative Strength Index (RSI)
- USEA 32.15
- IMRN 52.87
- Support Level
- USEA $1.72
- IMRN $2.05
- Resistance Level
- USEA $1.99
- IMRN $2.23
- Average True Range (ATR)
- USEA 0.09
- IMRN 0.16
- MACD
- USEA 0.00
- IMRN 0.02
- Stochastic Oscillator
- USEA 36.25
- IMRN 47.06
About USEA United Maritime Corporation
United Maritime Corp operates as a shipping company currently specializing in the seaborne transportation of dry bulk commodities. It currently operates one LR2 tanker vessel and three Capesize dry bulk vessels, two Kamsarmax dry bulk vessels, and three Panamax dry bulk vessels, with an aggregate cargo-carrying capacity of approximately 1,004,289 dwt.
About IMRN Immuron Limited
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.